Phase II study of imatinib mesylate [Imatinib] plus hydroxyurea [hydroxycarbamide] in the treatment of patients with recurrent/progressive grade II low grade glioma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

14 Mar 2013 Actual end date changed from Oct 2011 to Jun 2012 as reported by ClinicalTrials.gov.
19 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
24 Nov 2008 Status changed from recruiting to active, no longer recruiting, reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com